Presidential Letter

Welcome to what promises to be an exciting year for ISV! A big event for ISV is that our annual congress, Oct. 2-4, 2016, will be held in Boston. The Congress will be held in combined with two other meetings of high interest to ISV members: Vaccine Renaissance, organized annually by Prof. Annie DeGroot, and DNA Vaccines, organized by Prof. David Weiner. The Institute Pasteur, with its 33 member Institutes world-wide, will be a collaborator as well. ISV decided to run our Congress separately from Elsevier in order to maintain full scientific independence from the publishing company which is a for-profit entity. The combination of the Congress with the Vaccine Renaissance for its Tenth annual meeting, the DNA vaccine meeting, and the Institute Pasteur, in Boston, a city that is a hot spot for academic and industrial vaccine efforts (not to mention a fantastic tourist location) will ensure that attendees have both the usual incredible wealth of presentations and many opportunities to interact with potential collaborators. We will be structuring the meeting to ensure even more oral presentations selected from the submitted abstracts. The venue is the Marriott Longwharf- ideally located in the Boston Harbor, next to the famed New England Aquarium, Faneuil Hall, Quincy Market, and many other famous tourist sites, and at the peak of the spectacular autumn foliage. So plan on attending the ISV Congress! Register at:

As ISV has grown, we are implementing new programs for our members. At the Seoul meeting, we hosted a career development panel which was enthusiastically attended and will be held again in Boston. We will expand activities that reach out to trainees and young scientists. You will notice that the website will begin listing job postings; P.I.s and job seekers alike should keep this in mind. Only ISV members will be permitted to post positions, so remember to renew your ISV membership! We plan to also initiate a mentoring program which should be particularly useful for early career vaccinologists since our fields of activity are so diverse and include the spectrum of activities from bench research through manufacturing and clinical trials.

The Executive Board of ISV would like to encourage members to actively participate in the Society. The largest number of candidate to date for board positions and the increased attendance at the Society meeting during the Seoul Congress gave evidence of increased member involvement. Thank you! If you have an interest in participating on Society projects, please contact either myself or Ted Ross, ISV Secretary, to let us know what areas interest you. In February, the newsletter will list specific ISV committees and activities for which members can volunteer. Participation in Society activities is a terrific way to get to know international colleagues and to demonstrate your leadership.

I am writing this note on January 1, my first day of a two-year term as President of ISV. So I’d like to thank all of the previous officers and board members who have done so much to make ISV a vibrant organization. Thank you also to all of you who ran for office in the recent election demonstrating your interest in helping the Society. Appreciation is extended to those who will devote their time in the coming two years as officers, executive board members, and society volunteers. In our individual work, and together as ISV we will work together to more rapidly discover and develop vaccines to prevent and treat diseases around the world.

Wishing all of you the best in the coming year.


Margaret A. Liu, President ISV

ISV Presidential Travel Awards for 2016 ISV Congress

ISV Congress announces the establishment of the ISV Presidential Travel Awards for the 2016 ISV Congress. A total of 10 Presidential Awards of $500 each will be awarded to selected trainees who work in the field of vaccines. They will be chosen based upon evaluation of the submitted abstracts by the Scientific Committee. Candidates first must submit an abstract to After notification that their abstract is chosen for an oral or poster presentation, candidates can indicate their interest in applying for a Presidential Travel Award.  At that time, candidates will need to fill in information about their current training program (graduate school or post-doctoral training) to confirm their eligibility.  Award recipients will be notified by e-mail and honored during a session during the meeting. The awards will be provided as a reimbursement during the congress following submission of receipts related to meeting attendance.

Vaccine Renaissance Scholarship for Women and Minority Delegates


The organizers of Vaccine Renaissance have traditionally provided funding to women or under-represented minority delegates to attend its conferences. This year Vaccine Renaissance X will be held in conjunction with the 2016 ISV Annual Congress, and will continue to offer the same scholarship opportunities. This fund will be established to provide travel awards for selected delegates to attend this year’s conference in Boston.


Selected delegates will receive a $250 to $1,000 (USD) scholarship to be used to cover expenses related to attending Vaccine Renaissance X as part of the 2016 ISV Annual Congress (such as travel, lodging, and congress registration). After attending the conference, recipients will be reimbursed for the amount of the awarded scholarship and will need to submit proof of qualified expenses to scholarship organizer, Benjamin A. Morris [], to receive the reimbursement. Original receipts are required.


In order to qualify, you must be a woman or an under-represented minority working in the field of vaccine research and development.

Additionally, candidates must submit a 300-word essay describing their research and why they want to attend the conference, as well as the impact of the scholarship on their ability to attend. Essays should be submitted to Ryan Tassone [], via email, no later than August 01, 2016. A selection committee led by Dr. Annie DeGroot will review the submissions and determine the recipients, by September 01, 2016.